Sofia H L Frost1, Brian W Miller2, Tom A Bäck3, Erlinda B Santos4, Donald K Hamlin5, Sue E Knoblaugh6, Shani L Frayo4, Aimee L Kenoyer4, Rainer Storb7, Oliver W Press7, D Scott Wilbur5, John M Pagel7, Brenda M Sandmaier7. 1. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington sfrost@fredhutch.org. 2. Pacific Northwest National Laboratory, Richland, Washington College of Optical Sciences, University of Arizona, Tucson, Arizona. 3. Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 4. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. 5. Department of Radiation Oncology, University of Washington, Seattle, Washington. 6. Comparative Medicine Shared Resource, Fred Hutchinson Cancer Research Center, Seattle, Washington; and. 7. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington Department of Medicine, University of Washington, Seattle, Washington.
Abstract
UNLABELLED: α-radioimmunotherapy targeting CD45 may substitute for total-body irradiation in hematopoietic cell transplantation (HCT) preparative regimens for lymphoma. Our goal was to optimize the anti-CD45 monoclonal antibody (mAb; CA12.10C12) protein dose for (211)At-radioimmunotherapy, extending the analysis to include intraorgan (211)At activity distribution and α-imaging-based small-scale dosimetry, along with immunohistochemical staining. METHODS: Eight normal dogs were injected with either a 0.75 (n = 5) or 1.00 (n = 3) mg/kg dose of (211)At-B10-CA12.10C12 (11.5-27.6 MBq/kg). Two were euthanized and necropsied 19-22 h after injection, and 6 received autologous HCT 3 d after (211)At-radioimmunotherapy, after lymph node and bone marrow biopsies at 2-4 and/or 19 h after injection. Blood was sampled to study toxicity and clearance; CD45 targeting was evaluated by flow cytometry. (211)At localization and small-scale dosimetry were assessed using two α-imaging systems: an α-camera and an ionizing-radiation quantum imaging detector (iQID) camera. RESULTS: (211)At uptake was highest in the spleen (0.31-0.61% injected activity [%IA]/g), lymph nodes (0.02-0.16 %IA/g), liver (0.11-0.12 %IA/g), and marrow (0.06-0.08 %IA/g). Lymphocytes in blood and marrow were efficiently targeted using either mAb dose. Lymph nodes remained unsaturated but displayed targeted (211)At localization in T lymphocyte-rich areas. Absorbed doses to blood, marrow, and lymph nodes were estimated at 3.1, 2.4, and 3.4 Gy/166 MBq, respectively. All transplanted dogs experienced transient hepatic toxicity. Liver enzyme levels were temporarily elevated in 5 of 6 dogs; one treated with 1.00 mg mAb/kg developed ascites and was euthanized 136 d after HCT. CONCLUSION: (211)At-anti-CD45 radioimmunotherapy with 0.75 mg mAb/kg efficiently targeted blood and marrow without severe toxicity. Dosimetry calculations and observed radiation-induced effects indicated that sufficient (211)At-B10-CA12.10C12 localization was achieved for efficient conditioning for HCT.
UNLABELLED: α-radioimmunotherapy targeting CD45 may substitute for total-body irradiation in hematopoietic cell transplantation (HCT) preparative regimens for lymphoma. Our goal was to optimize the anti-CD45 monoclonal antibody (mAb; CA12.10C12) protein dose for (211)At-radioimmunotherapy, extending the analysis to include intraorgan (211)At activity distribution and α-imaging-based small-scale dosimetry, along with immunohistochemical staining. METHODS: Eight normal dogs were injected with either a 0.75 (n = 5) or 1.00 (n = 3) mg/kg dose of (211)At-B10-CA12.10C12 (11.5-27.6 MBq/kg). Two were euthanized and necropsied 19-22 h after injection, and 6 received autologous HCT 3 d after (211)At-radioimmunotherapy, after lymph node and bone marrow biopsies at 2-4 and/or 19 h after injection. Blood was sampled to study toxicity and clearance; CD45 targeting was evaluated by flow cytometry. (211)At localization and small-scale dosimetry were assessed using two α-imaging systems: an α-camera and an ionizing-radiation quantum imaging detector (iQID) camera. RESULTS: (211)At uptake was highest in the spleen (0.31-0.61% injected activity [%IA]/g), lymph nodes (0.02-0.16 %IA/g), liver (0.11-0.12 %IA/g), and marrow (0.06-0.08 %IA/g). Lymphocytes in blood and marrow were efficiently targeted using either mAb dose. Lymph nodes remained unsaturated but displayed targeted (211)At localization in T lymphocyte-rich areas. Absorbed doses to blood, marrow, and lymph nodes were estimated at 3.1, 2.4, and 3.4 Gy/166 MBq, respectively. All transplanted dogs experienced transient hepatic toxicity. Liver enzyme levels were temporarily elevated in 5 of 6 dogs; one treated with 1.00 mg mAb/kg developed ascites and was euthanized 136 d after HCT. CONCLUSION: (211)At-anti-CD45 radioimmunotherapy with 0.75 mg mAb/kg efficiently targeted blood and marrow without severe toxicity. Dosimetry calculations and observed radiation-induced effects indicated that sufficient (211)At-B10-CA12.10C12 localization was achieved for efficient conditioning for HCT.
Authors: Wolfgang A Bethge; D Scott Wilbur; Rainer Storb; Donald K Hamlin; Erlinda B Santos; Martin W Brechbiel; Brenda M Sandmaier Journal: Transplantation Date: 2004-08-15 Impact factor: 4.939
Authors: Hirohisa Nakamae; Fabio R Kerbauy; D Scott Wilbur; Wolfgang Bethge; Donald K Hamlin; Erlinda B Santos; Rainer Storb; Brenda M Sandmaier Journal: Transplantation Date: 2010-06-15 Impact factor: 4.939
Authors: D Scott Wilbur; Ming-Kuan Chyan; Hirohisa Nakamae; Yun Chen; Donald K Hamlin; Erlinda B Santos; Brian T Kornblit; Brenda M Sandmaier Journal: Bioconjug Chem Date: 2012-02-10 Impact factor: 4.774
Authors: George Sgouros; John C Roeske; Michael R McDevitt; Stig Palm; Barry J Allen; Darrell R Fisher; A Bertrand Brill; Hong Song; Roger W Howell; Gamal Akabani; Wesley E Bolch; A Bertrand Brill; Darrell R Fisher; Roger W Howell; Ruby F Meredith; George Sgouros; Barry W Wessels; Pat B Zanzonico Journal: J Nucl Med Date: 2010-01-15 Impact factor: 10.057
Authors: Nicolas Chouin; Sture Lindegren; Sofia H L Frost; Holger Jensen; Per Albertsson; Ragnar Hultborn; Stig Palm; Lars Jacobsson; Tom Bäck Journal: J Nucl Med Date: 2013-06-12 Impact factor: 10.057
Authors: Aya Nakaya; Huiying Qiu; Erlinda B Santos; Donald K Hamlin; D Scott Wilbur; Rainer Storb; Brenda M Sandmaier Journal: Transplant Cell Ther Date: 2021-02-25
Authors: Alexander N Garcia; Nancy G Casanova; Daniel G Valera; Xiaoguang Sun; Jin H Song; Carrie L Kempf; Liliana Moreno-Vinasco; Kimberlie Burns; Tadeo Bermudez; Mia Valdez; Genesis Cuellar; Taylor Gregory; Radu C Oita; Vivian Reyes Hernon; Christy Barber; Sara M Camp; Diego Martin; Zhonglin Liu; Christian Bime; Saad Sammani; Anne E Cress; Joe Gn Garcia Journal: Transl Res Date: 2021-06-15 Impact factor: 7.012
Authors: Stephanie Lamart; Brian W Miller; Anne Van der Meeren; Anissa Tazrart; Jaime F Angulo; Nina M Griffiths Journal: PLoS One Date: 2017-10-12 Impact factor: 3.240